drugset / Trial / NCT00536601

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Completed 174 enrolled Roswell Park Cancer Institute National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with hematologic cancer or solid tumors. Giving high-dose chemotherapy with or without TBI before ASCT stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood or bone marrow and stored. More chemotherapy may be given to prepare for the stem cell transplant. The stem cells are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy.

Timeline

Start: 2006-06-29
Primary completion: 2018-07-09
Completion: 2018-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Busulfan	Small molecule	—	Intravenous
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	Intravenous
Subject	Melphalan	Small molecule	120 mg/m2	Intravenous
Subject	Melphalan	Small molecule	200 mg/m2	Intravenous
Subject	Thiotepa	Other / unclassified	—	Intravenous
Subject	carmustine	Small molecule	—	Intravenous

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Summary

Timeline

Drugs

Indications